Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Hold Rating by StockNews.com

StockNews.com cut shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a hold rating in a research note released on Tuesday morning.

Several other analysts have also weighed in on the stock. Truist Financial upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, December 19th. Finally, Barclays upped their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Sangamo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Sangamo Therapeutics Trading Up 5.2 %

Shares of SGMO stock opened at $2.63 on Tuesday. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company has a market capitalization of $548.74 million, a P/E ratio of -3.51 and a beta of 1.15. The stock has a 50 day moving average of $2.10 and a two-hundred day moving average of $1.19.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. During the same period last year, the business earned ($0.34) earnings per share. Sell-side analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC bought a new stake in Sangamo Therapeutics during the second quarter worth about $67,000. Meritage Portfolio Management boosted its holdings in shares of Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Sangamo Therapeutics during the 2nd quarter worth approximately $89,000. XTX Topco Ltd increased its holdings in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the last quarter. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.